Medicine

Lessons from an unfavorable gene treatment trial for Duchenne muscle dystrophy

.Nature Medication, Published online: 09 October 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec received FDA confirmation after a damaging test, which highlights the many complications as well as challenges of medication development in this particular environment.

Articles You Can Be Interested In